Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-07-27

Clinical Trial Update: An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+ [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a Listeria monocytogenes-based vaccine for cervical intraepithelial neoplasia (CIN 2+) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AXAL (axalimogene filolisbac)

Snippet

Sponsor: Advaxis, Inc. | Conditions: Cervical Intraepithelial Neoplasia | Phase 2 | Status: TERMINATED